A new company spun out of the University of Miami is taking the work of a Nobel Prize-winning endocrinologist and turning it into drug candidates for treatment of cancer and heart disease. Dr. Andrew V. Schally is a pioneer in the field of growth hormone-releasing hormone drugs (GHRH), winning the Nobel Prize in physiology or […]
A stealth mode Simi Valley, California startup wants to disrupt the field of how benign prostatic hyperplasia (BPH) is treated. The traditional methods include drug therapy and when that fails, surgical procedures involving the urethra and heat energy. But adapting techniques from orthopedics and ophthalmology, UroTech Surgical has developed a minimally invasive device that can reduce […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
According to the CDC, prostate cancer represents the most common non-skin cancer in American men and the second leading cause of death in US men. Recent research initiatives have shed some light on the mechanisms of this disease and possible therapies for treating both localized and metastatic prostate cancers. Even so, researchers and scientists remain […]
Among the three most common types of prostate cancer treatment, external beam radiation therapy is the most toxic and costly, according to a Cleveland Clinic researcher. Dr. Jay Ciezki and colleagues analyzed the Medicare records of more than 137,000 men who received one of three prostate cancer treatments — external beam radiation therapy; prostatectomy, or […]
The prostate cancer test to confirm a diagnosis is an uncomfortable medical procedure with an equally awkward name — the transrectal biopsy. This intrusive test uses an ultrasound probe and needle to retrieve a tissue sample for analysis. Even when the biopsy causes no pain, it sparks plenty of patient anxiety. Duke University researchers have […]
Celgene (NASDAQ:CELG), a Summit, New Jersey-based pharmaceutical company, has stopped a phase 3 trial of its blockbuster drug Revlamid for castrate-resistant prostate cancer after data showed the drug had failed to prolong life. The double-blind study was evaluating the efficacy and safety of the drug in combination with chemotherapy drug Docetaxel and the steroid Prednisone. […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.